GlassScriptPhysician profile
Anusha Madadi
NPI 1447416334
$57,194.86
in general payments reported to CMS, 2019-2025
25 companies · $7,198 in 2025
The $7,198 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $10K · 2021: $13K · 2022: $6,058 · 2023: $200 · 2024: $11K · 2025: $7,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $2,258 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $598 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,885.00 |
| Travel and Lodging | $2,258.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $598.32 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,995.84 | 2019-2025 | Imfinzi, Calquence |
| Incyte Corporation | $10,169.83 | 2020-2022 | |
| Acceleron Pharma, INC. | $7,250.00 | 2020-2021 | |
| Celgene Corporation | $6,983.32 | 2019-2020 | |
| Kyowa Kirin, INC. | $4,161.80 | 2019 | |
| Avyxa Pharma, LLC | $3,710.37 | 2025 | |
| Exelixis INC. | $1,980.00 | 2021 | |
| Janssen Biotech, INC. | $1,911.01 | 2019-2025 | Rybrevant |
| Beigene USA, INC. | $1,650.00 | 2020 | |
| Gilead Sciences, INC. | $1,011.92 | 2021 | |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Beigene, LTD. | $975.00 | 2020-2021 | |
| Astellas Pharma US INC | $500.00 | 2021 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Glaxosmithkline, LLC. | $450.00 | 2025 | Ojjaara |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $272.67 | 2019-2024 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Daiichi Sankyo INC. | $200.00 | 2023 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Lilly USA, LLC | $21.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.20 | 2019 | |
| Genentech, INC. | $18.11 | 2019 | |
| Roche Diagnostics Corporation | $17.56 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Genentech USA, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anusha Madadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.